Literature DB >> 16916757

Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.

Vincenzo Bronte1, Sara Cingarlini, Ilaria Marigo, Carmela De Santo, Giovanna Gallina, Luigi Dolcetti, Stefano Ugel, Elisa Peranzoni, Susanna Mandruzzato, Paola Zanovello.   

Abstract

The interaction between tumor cells and the nearby environment is being actively investigated to explore how this interplay affects the initiation and progression of cancer. Host-tumor relationship results in the production of pro-inflammatory cytokines and chemokines that promote the recruitment of leukocytes within and around developing neoplasms. Cancer cells, together with newly recruited tumor-infiltrating cells, can also activate fibroblast and vascular responses, thus resulting in a chronic microenvironment perturbation. In this complex scenario, interactions between innate and adaptive immune cells can be disturbed, leading to a failure of immune-mediated tumor recognition and destruction. On the basis of the recent awareness about tumor promotion and immune deregulation by immune/inflammatory cells, novel anti-cancer strategies can be exploited.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16916757     DOI: 10.1080/08820130600754994

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  12 in total

Review 1.  Leukocytes in mammary development and cancer.

Authors:  Lisa M Coussens; Jeffrey W Pollard
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-03-01       Impact factor: 10.005

Review 2.  Advancements in immune tolerance.

Authors:  Ping-Ying Pan; Junko Ozao; Zuping Zhou; Shu-Hsia Chen
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

Review 3.  Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies.

Authors:  Simone Caligola; Francesco De Sanctis; Stefania Canè; Stefano Ugel
Journal:  Front Genet       Date:  2022-05-16       Impact factor: 4.772

Review 4.  Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.

Authors:  David G DeNardo; Pauline Andreu; Lisa M Coussens
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

5.  Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2.

Authors:  Eliane Angst; Howard A Reber; Oscar J Hines; Guido Eibl
Journal:  Surgery       Date:  2008-06-05       Impact factor: 3.982

Review 6.  Signaling defects in anti-tumor T cells.

Authors:  Alan B Frey; Ngozi Monu
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

7.  Phenotypic and functional delineation of murine CX(3)CR1 monocyte-derived cells in ovarian cancer.

Authors:  Kevin M Hart; S Peter Bak; Anselmo Alonso; Brent Berwin
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

8.  CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.

Authors:  Po-Hao Feng; Kang-Yun Lee; Ya-Ling Chang; Yao-Fei Chan; Lu-Wei Kuo; Ting-Yu Lin; Fu-Tsai Chung; Chih-Shi Kuo; Chih-Teng Yu; Shu-Min Lin; Chun-Hua Wang; Chun-Liang Chou; Chien-Da Huang; Han-Pin Kuo
Journal:  Am J Respir Crit Care Med       Date:  2012-09-06       Impact factor: 21.405

Review 9.  The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment.

Authors:  Francesco De Sanctis; Sara Sandri; Giovanna Ferrarini; Irene Pagliarello; Silvia Sartoris; Stefano Ugel; Ilaria Marigo; Barbara Molon; Vincenzo Bronte
Journal:  Front Immunol       Date:  2014-02-24       Impact factor: 7.561

10.  S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB.

Authors:  Po-Hao Feng; Chih-Teng Yu; Kuan-Yuan Chen; Ching-Shan Luo; Shen Ming Wu; Chien-Ying Liu; Lu Wei Kuo; Yao-Fei Chan; Tzu-Tao Chen; Chih-Cheng Chang; Chun-Nin Lee; Hsiao-Chi Chuang; Chiou-Feng Lin; Chia-Li Han; Wei-Hwa Lee; Kang-Yun Lee
Journal:  Oncotarget       Date:  2018-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.